AU2022310901A1 - Treatment of inflammatory diseases - Google Patents

Treatment of inflammatory diseases Download PDF

Info

Publication number
AU2022310901A1
AU2022310901A1 AU2022310901A AU2022310901A AU2022310901A1 AU 2022310901 A1 AU2022310901 A1 AU 2022310901A1 AU 2022310901 A AU2022310901 A AU 2022310901A AU 2022310901 A AU2022310901 A AU 2022310901A AU 2022310901 A1 AU2022310901 A1 AU 2022310901A1
Authority
AU
Australia
Prior art keywords
compound
inhibitors
per day
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022310901A
Other languages
English (en)
Inventor
Justine DAO
René Alexandre GALIEN
Edouard HELLOT
Magdalena Yonkova PETKOVA
Natalia RUEDA RINCON
Christian Alexander SEEMAYER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lakefront Biotherapeutics NV
Original Assignee
Lakefront Biotherapeutics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lakefront Biotherapeutics NV filed Critical Lakefront Biotherapeutics NV
Publication of AU2022310901A1 publication Critical patent/AU2022310901A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2022310901A 2021-07-12 2022-07-11 Treatment of inflammatory diseases Pending AU2022310901A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21305971 2021-07-12
EP21305971.0 2021-07-12
EP22315039.2 2022-02-24
EP22315039 2022-02-24
PCT/EP2022/069362 WO2023285405A1 (en) 2021-07-12 2022-07-11 Treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
AU2022310901A1 true AU2022310901A1 (en) 2024-02-22

Family

ID=82748704

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022310901A Pending AU2022310901A1 (en) 2021-07-12 2022-07-11 Treatment of inflammatory diseases

Country Status (9)

Country Link
US (1) US20240325404A1 (enExample)
EP (1) EP4370128A1 (enExample)
JP (1) JP2024524631A (enExample)
KR (1) KR20240035480A (enExample)
AU (1) AU2022310901A1 (enExample)
CA (1) CA3225221A1 (enExample)
IL (1) IL309946A (enExample)
MX (1) MX2024000517A (enExample)
WO (1) WO2023285405A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
JP2024524631A (ja) 2024-07-05
MX2024000517A (es) 2024-01-31
EP4370128A1 (en) 2024-05-22
US20240325404A1 (en) 2024-10-03
KR20240035480A (ko) 2024-03-15
IL309946A (en) 2024-03-01
WO2023285405A1 (en) 2023-01-19
CA3225221A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
JP2021042222A (ja) Ｍｄｍ２阻害剤およびその組み合わせ物
ES2362898T3 (es) Nuevo uso combinado de un compuesto de sulfonamina en el tratamiento de cáncer.
US20230346820A1 (en) Methods and compositions for the treatment of sars-cov-2
CN121335903A (zh) Kras调节化合物
KR102961896B1 (ko) 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
US20210290651A1 (en) Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
EP3308786A1 (en) Fgfr regulaton for the treatment of viral infections
CN111053768A (zh) 用于治疗黑素瘤的药物组合
US20240390378A1 (en) Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
TW201605454A (zh) 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
TW202342047A (zh) 使用經取代之嘧啶-4(3h)-酮及索托拉西布(sotorasib)之組合療法
Wang et al. Discovery, optimization, and evaluation of novel N-(Benzimidazol-5-yl)-1, 3, 4-thiadiazol-2-amine analogues as potent STAT3 inhibitors for cancer treatment
Yuan et al. New drug approvals for 2022: Synthesis and clinical applications
Penman et al. Safety perspectives on presently considered drugs for the treatment of COVID‐19
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
Grajales et al. Unveiling abrocitinib: a thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)
US20220133751A1 (en) Methods of treating myeloproliferative disorders
US20230158103A1 (en) Pld for use in combination in the treatment of coronavirus
WO2023161326A1 (en) Compound for use in and methods of treatment of inflammatory diseases
CN117677387A (zh) 炎性疾病的治疗
US20240325404A1 (en) Treatment of inflammatory diseases
JP2018528949A (ja) Ｐｉ３ｋ阻害剤およびｍｄｍ２阻害剤を使用する組み合わせ療法
WO2025103408A9 (zh) 治疗alk阳性或ros1阳性的非小细胞肺癌的方法
EP4135703A1 (en) Methods and formulations for administration of thiocarbamate derivatives a2a inhibitors
US20250186475A1 (en) Methods of treating medical conditions using islatravir or a related compound

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANTS TO LAKEFRONT BIOTHERAPEUTICS NV